The future of weight loss with medication is developing rapidly. Only a few years ago, there were very limited medication-based options available. Today, active ingredients such as semaglutide and tirzepatide are shaping medical weight loss. At the same time, new medications, tablets and combination therapies are being developed that could further change the treatment of overweight and obesity.
It is important to keep a realistic perspective: new weight loss medications are not a replacement for medical assessment, nutrition, physical activity and long-term support. However, for suitable patients, they can be an important part of a structured treatment program. What matters is which option is approved, available, medically appropriate and individually suitable.
This article explains which developments are currently most relevant, what role Wegovy, Mounjaro, Wegovy Pill, retatrutide and orforglipron could play, and why medical supervision remains essential despite new active ingredients.
Table of Contents
- Why Is Treatment With Weight Loss Medications Changing?
- Where Do We Stand Today?
- Wegovy Pill: The Step Toward Oral GLP-1 Therapy
- Orforglipron: A New Generation of Oral Active Ingredients?
- Retatrutide: A Triple Agonist With Strong Potential
- Combination Therapies: More Than Just GLP-1
- What Does This Mean for Patients?
- Which Risks and Limitations Remain?
- Why Medical Supervision Is Becoming Even More Important
- Medically Supervised Weight Loss at The Body Clinic
- Conclusion
- Frequently Asked Questions
Why Is Treatment With Weight Loss Medications Changing?
Overweight and obesity are complex medical issues. Body weight is influenced not only by calorie intake and physical activity, but also by hunger and satiety signals, metabolism, hormones, medications, sleep, stress, genetic factors and the personal environment. This is why a purely willpower-based view is often not enough.
Modern medications increasingly target biological signaling pathways that influence hunger, satiety, blood glucose regulation, gastric emptying and energy balance. GLP-1 receptor agonists are among the best-known examples. They mimic signals that play a role after eating and can support feelings of fullness, among other effects.
However, the future goes beyond individual GLP-1 active ingredients. New medications combine several signaling pathways, are being developed as tablets or are intended to fit more easily into everyday life over the long term. This makes treatment more differentiated, but also more in need of explanation.
Where Do We Stand Today?
Several medications are already relevant in the context of medical weight loss. They differ in active ingredient, approval, application, side effect profile and individual suitability.
| Medication | Active Ingredient | Classification | Use |
|---|---|---|---|
| Wegovy | Semaglutide | GLP-1 receptor agonist for weight management in suitable patients. | Injection, usually once weekly. |
| Mounjaro | Tirzepatide | Dual GIP and GLP-1 receptor agonist for weight management in suitable patients. | Injection, usually once weekly. |
| Saxenda | Liraglutide | GLP-1 receptor agonist for weight reduction. | Injection, usually once daily. |
| Ozempic | Semaglutide | Primarily approved for the treatment of type 2 diabetes and should not be equated with Wegovy. | Injection, usually once weekly. |
You can find an overview of existing options on our page about weight loss medications. The active ingredients semaglutide and tirzepatide are particularly important for medical classification.
Wegovy Pill: The Step Toward Oral GLP-1 Therapy
One of the most important developments is the oral form of semaglutide for weight management. The Wegovy Pill is relevant because many patients may find a tablet easier or more comfortable than an injection. For people with needle anxiety, travel requirements or difficulties handling pens, an oral option may become attractive in the future.
At the same time, a tablet does not automatically mean that treatment is simple or suitable for everyone. Oral GLP-1 medications remain prescription medicines. Use, dosage, possible side effects, interactions and suitability must be assessed medically.
In May 2026, the EMA recommended extending the Wegovy authorization to include an oral formulation. This brings the first oral GLP-1 option for weight management in the EU within reach. You can find more information on our page about the Wegovy Pill.
Orforglipron: A New Generation of Oral Active Ingredients?
Orforglipron is another interesting active ingredient in development. Unlike classic peptide-based GLP-1 active ingredients, it is an oral, small-molecule GLP-1 receptor agonist. Put simply: orforglipron is being studied as a tablet and could eventually become another oral option for the treatment of obesity.
Phase 3 data show that orforglipron led to greater weight reduction than placebo in adults with obesity. At the same time, side effects were observed that broadly fit the known profile of GLP-1-based therapies, especially gastrointestinal symptoms.
However, it is important to understand that orforglipron is not simply a freely available alternative to existing weight loss medications. As long as a medication is not approved and regularly available, it should not be obtained through unsafe sources, research products or unofficial offers. You can find more information on our page about orforglipron.
Retatrutide: A Triple Agonist With Strong Potential
Retatrutide is one of the most closely watched active ingredients in the pipeline. It is referred to as a triple agonist because it acts on three receptor systems: GLP-1, GIP and glucagon. This distinguishes it from pure GLP-1 receptor agonists and also from dual active ingredients such as tirzepatide.
In studies, retatrutide showed strong effects on body weight. Current phase 3 data suggest pronounced weight reduction in adults with obesity. However, such results do not mean that the active ingredient is already regularly available or suitable for every person.
For new active ingredients, efficacy, safety, long-term data, side effects, approval, availability and practical use must be assessed carefully. Patients should therefore not understand retatrutide as a short-term self-directed solution, but as a possible future component of medically supervised obesity treatment. You can find more information on our page about retatrutide.
Combination Therapies: More Than Just GLP-1
Another future area is combination therapy. Several hormonal signaling pathways are combined to influence hunger, satiety, metabolism and energy balance in a more targeted way. Examples include combinations of GLP-1-based active ingredients with amylin analogues or active ingredients with several receptor targets.
One example in development is CagriSema, a combination of cagrilintide and semaglutide. Such approaches show that the future of weight loss medications will probably not consist only of “more GLP-1”, but of more differentiated mechanisms of action.
For patients, however, this does not automatically mean that new combinations are always better. What matters is whether a medication is approved, safe, available and individually suitable. Stronger effects can also be associated with side effects, cost questions and the need for maintenance strategies.
What Does This Mean for Patients?
The coming years may bring more choice. In principle, this is positive because not every person responds to a medication in the same way. Some patients benefit more from one active ingredient, while others experience side effects or prefer a different form of administration.
However, more choice also means a greater need for medical guidance. In the future, the question will be less: “Which medication is strongest?” The more important question will be: “Which medication fits my medical situation, my risks and my everyday life?”
| Development | Possible Benefit | Important Context |
|---|---|---|
| Oral GLP-1 medications | Tablets may be more practical than injections for some people. | Tablets also remain prescription medicines and must be used correctly. |
| Dual and triple agonists | Several signaling pathways may enable stronger effects. | A stronger effect does not automatically mean better suitability for every person. |
| Combination therapies | New mechanisms of action may allow more individualized treatment. | Long-term data, side effects, costs and availability remain decisive. |
| More treatment options | Treatments can be personalized more precisely. | Medical assessment becomes even more important. |
Which Risks and Limitations Remain?
Even new weight loss medications do not solve every problem. Common side effects of GLP-1-based therapies affect the gastrointestinal tract, for example nausea, vomiting, diarrhea, constipation or abdominal pain. Depending on the active ingredient and the individual person, further risks may occur.
The question of long-term weight stabilization also remains central. Studies show that weight is often regained after stopping medication if no sustainable maintenance strategy is in place. The future of medication-assisted weight loss will therefore depend not only on new active ingredients, but also on better concepts for the period after the active weight loss phase.
Another key point is safety. The greater the demand, the more dubious offers appear. Falsified medications, products without a prescription, social media sales, powders or alleged research products can be dangerous. You may also find our articles on falsified Ozempic and the risky trend of making your own weight loss injections helpful.
Why Medical Supervision Is Becoming Even More Important
The more medications become available, the more important medical selection becomes. An active ingredient can be highly effective and still unsuitable for a particular person. Reasons may include existing conditions, current medications, side effects, pregnancy, breastfeeding, eating behavior, mental health burden or individual treatment goals.
Medical supervision helps weigh benefits and risks realistically. It also ensures that dosage, use, side effects and progress are monitored. Especially when appetite is strongly reduced, it is important that patients continue to get enough nutrients.
This is why nutritional counseling despite GLP-1 medications and preserving muscle mass remain important. You can read more in the article on how to preserve muscle mass in a calorie deficit.
Medically Supervised Weight Loss at The Body Clinic
At The Body Clinic, the focus is on a structured and medically supervised approach. This means that we do not view weight loss medications as a quick stand-alone solution, but as a possible part of a comprehensive treatment concept.
Before treatment begins, it is assessed whether medical weight loss may be suitable and which option could make sense. Factors such as BMI, comorbidities, previous weight loss attempts, medications, side effect risks and personal goals all play a role.
You can find information about our program on the page medically supervised weight loss. If you would like to know what costs may arise, you can find our overview of the costs of medical weight loss. If you would like to check whether treatment may generally be suitable for you, you can check your eligibility for medical weight loss.
Conclusion
The future of weight loss with medication is becoming more diverse. In addition to established injections such as Wegovy and Mounjaro, oral options such as the Wegovy Pill and orforglipron, as well as new multi-agonists such as retatrutide, are increasingly coming into focus. Combination therapies could also further change treatment in the future.
What remains decisive, however, is this: new weight loss medications are not a self-directed solution, but belong within a medically supervised overall concept. The most important question is not which medication promises the greatest weight loss, but which therapy is safe, appropriate, available and individually suitable.
Frequently Asked Questions
Which New Weight Loss Medications Could Become Important in the Future?
Currently, oral GLP-1 options such as the Wegovy Pill, the active ingredient orforglipron being studied in trials, multi-agonists such as retatrutide and combination therapies such as CagriSema are particularly relevant. Which medications actually become available and for whom they are suitable depends on approval, safety, availability and individual medical assessment.
Will There Be Weight Loss Medications as Tablets?
Yes, oral options are becoming increasingly important. In 2026, the EMA recommended an oral formulation of Wegovy for weight management. Orforglipron is also being studied as an oral GLP-1 active ingredient. Nevertheless, such medications remain prescription medicines and require medical supervision.
Is Retatrutide Better Than Wegovy or Mounjaro?
This cannot currently be answered in general terms. Retatrutide showed strong weight reduction in studies, but it is a different active ingredient with a different development and approval status. Whether a medication is suitable depends not only on average weight loss in studies, but also on safety, side effects, availability and the individual situation.
Will New Medications Replace Nutrition and Physical Activity?
No. Even new weight loss medications do not replace a sustainable lifestyle. Nutrition, physical activity, muscle preservation, sleep, stress management and medical follow-up remain important parts of sustainable weight loss.
Why Is Medical Supervision So Important With New Weight Loss Medications?
New medications can be effective, but they are not automatically suitable for every person. Medical supervision helps assess indication, risks, side effects, dosage and progress correctly. It also protects against self-medication, unrealistic expectations and unsafe sources.
Sources
- First oral GLP-1 treatment for weight management, European Medicines Agency
- Wegovy EPAR, European Medicines Agency
- Mounjaro EPAR, European Medicines Agency
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity, New England Journal of Medicine
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity, New England Journal of Medicine
- Retatrutide Phase 3 obesity trial results, Eli Lilly
- CagriSema regulatory update, Novo Nordisk
- Obesity, World Health Organization